Condition: High Risk Prostate Carcinoma · Sponsor: Haaglanden Medical Centre
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments. * patients will be irradiated on the prostate and (elective) lymph nodes more concentrated but with fewer hospital visits (hypofractionation) * the tumor will get a higher dose * androgen deprivation therapy will be reduced as much al possible preventing side effects Researchers will compare oncological outcome and toxicity.
This description comes directly from the study's public registry record.
Ursula J Fisscher, PhD · 0031889792357 · u.fisscher@haaglandenmc.nl
Mirjam E Mast, PhD · +31 88 9792357 · m.mast@haaglandenmc.nl
Always discuss trial participation with your own doctor first.
| Haaglanden Medical Centre | Leidschendam, South Holland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06204341